Medicine
Syfovre 450 mg/3 mL injection
Syfovre 450 mg/3 mL injection is a prescription medicine containing Pegcetacoplan for intravitreal use, marketed by Apellis Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store the vial in the original carton to protect from light. Do not shake.
Key facts
- Active ingredient (INN)
- Pegcetacoplan
- Brand
- Syfovre
- Strength
- 450 mg/3 mL
- Dosage form
- Injection
- Route
- Intravitreal
- Packs
- 1 vial of 3 mL
- Marketing authorisation holder
- Apellis Pharmaceuticals
- Manufacturer
- Apellis Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store the vial in the original carton to protect from light. Do not shake.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AJ03 Pegcetacoplan
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 February 2023
- Identifiers
- RxCUI 2630847, 2630853DailyMed set ID b4434e61-9ec9-4e0e-bd60-45aaa0a87e64NDC 73606-020Application NDA217171
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 3 mL in 1 vial, glass | 73606-020-01 | Apellis Pharmaceuticals | 17 February 2023 |
| 1 vial, glass in 1 carton / 3 mL in 1 vial, glass | 73606-020-02 | Apellis Pharmaceuticals | 7 November 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Pegcetacoplan
Clinical summary
Pegcetacoplan is a complement inhibitor indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH), among other approved uses. It is available as injection for intravitreal and subcutaneous use. MedsAcross supplies Pegcetacoplan for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about PegcetacoplanFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Empaveli prescribing information (Apellis Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Aspaveli: European public assessment report (EPAR) · European Medicines Agency
Need Syfovre 450 mg/3 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.